Susquehanna International Group
ALLO icon

Susquehanna International Group’s Allogene Therapeutics ALLO Stock Holding History

Susquehanna International Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Buy
126,760
+35,507
+39% +$71.2K ﹤0.01% 10791
2025
Q4 		$125K Buy
91,253
+22,753
+33% +$30K ﹤0.01% 11318
2025
Q3 		$84.9K Sell
68,500
-236,312
-78% -$282K ﹤0.01% 11655
2025
Q2 		$344K Buy
304,812
+147,168
+93% +$196K ﹤0.01% 10031
2025
Q1 		$230K Buy
157,644
+4,042
+3% +$7.62K ﹤0.01% 10640
2024
Q4 		$327K Buy
153,602
+71,146
+86% +$175K ﹤0.01% 9634
2024
Q3 		$231K Sell
82,456
-5,286
-6% -$14.1K ﹤0.01% 10168
2024
Q2 		$204K Sell
87,742
-8,064
-8% -$23.8K ﹤0.01% 10312
2024
Q1 		$428K Sell
95,806
-153,505
-62% -$641K ﹤0.01% 8880
2023
Q4 		$800K Sell
249,311
-77,055
-24% -$219K ﹤0.01% 7540
2023
Q3 		$1.03M Sell
326,366
-11,610
-3% -$50.9K ﹤0.01% 6559
2023
Q2 		$1.68M Sell
337,976
-161,958
-32% -$876K ﹤0.01% 5515
2023
Q1 		$2.47M Buy
499,934
+434,954
+669% +$2.79M ﹤0.01% 4712
2022
Q4 		$409K Sell
64,980
-138,239
-68% -$1.28M ﹤0.01% 8347
2022
Q3 		$2.19M Buy
203,219
+41,307
+26% +$561K ﹤0.01% 4724
2022
Q2 		$1.85M Sell
161,912
-17,108
-10% -$152K ﹤0.01% 5085
2022
Q1 		$1.63M Sell
179,020
-65,309
-27% -$680K ﹤0.01% 5937
2021
Q4 		$3.65M Buy
244,329
+142,706
+140% +$2.52M ﹤0.01% 4303
2021
Q3 		$2.61M Buy
101,623
+15,997
+19% +$380K ﹤0.01% 5255
2021
Q2 		$2.23M Sell
85,626
-68,624
-44% -$1.96M ﹤0.01% 5665
2021
Q1 		$5.45M Buy
154,250
+92,410
+149% +$3.12M ﹤0.01% 3739
2020
Q4 		$1.56M Buy
61,840
+40,388
+188% +$1.32M ﹤0.01% 5650
2020
Q3 		$809K Sell
21,452
-2,761
-11% -$104K ﹤0.01% 6641
2020
Q2 		$1.04M Sell
24,213
-23,710
-49% -$857K ﹤0.01% 5839
2020
Q1 		$932K Buy
+47,923
New +$1.14M ﹤0.01% 5573
2019
Q4 		– Sell
-30,447
Closed -$839K – 9639
2019
Q3 		$830K Sell
30,447
-11,234
-27% -$320K ﹤0.01% 6109
2019
Q2 		$1.12M Buy
+41,681
New +$1.16M ﹤0.01% 5395

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's ALLO Position: Q1 2026 in Review

Susquehanna International Group increased its Allogene Therapeutics (ALLO) stake by 39% in Q1 2026, buying an estimated $71.2K and bringing the position to 126,760 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #10791.

Susquehanna International Group first reported a position in ALLO in Q2 2019 and has held it in 27 quarters since. The position peaked at $5.45M in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Susquehanna International Group held 126,760 shares of Allogene Therapeutics worth $309K as of Q1 2026.
  • Susquehanna International Group bought 35,507 Allogene Therapeutics shares in Q1 2026, an estimated $71.2K.
  • Allogene Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10791 holding.
  • Susquehanna International Group first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Susquehanna International Group's Allogene Therapeutics position peaked at $5.45M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.